Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Arginine glutamate** is a 1:1 amino-acid salt of L-arginine and L-glutamic acid administered as an intravenous injection for adjunctive management of hyperammonemia associated with chronic liver disease. Following intravenous administration, it dissociates into arginine and glutamic acid. Its ammonia-lowering activity is attributed to support of hepatic nitrogen disposal, including increased hepatic arginase activity and provision of arginine for urea-cycle ammonia detoxification. Chinese post-marketing clinical research has evaluated arginine glutamate injection in cirrhosis-associated mild hepatic encephalopathy versus L-ornithine-L-aspartate, with reported noninferiority for clinical improvement, ammonia reduction, and number connection test improvement. ([m-pharma.com.cn](https://www.m-pharma.com.cn/uploads/%E8%AF%B4%E6%98%8E%E4%B9%A6/11.%20%E7%B2%BE%E6%B0%A8%E9%85%B8%E8%B0%B7%E6%B0%A8%E9%85%B8%E6%B3%A8%E5%B0%84%E6%B6%B2%E8%AF%B4%E6%98%8E%E4%B9%A6.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arginine glutamate (Beijing YouAn Hospital).